Tergus pharma. MedPharm, Ltd. Tergus lead investor Gre...

Tergus pharma. MedPharm, Ltd. Tergus lead investor Great Point Partners will retain a significant minority ownership stake in the newly combined MedPharm, while private equity firms Ampersand Capital Partners and Bourne CDMO Tergus Pharma plans to merge with MedPharm, a U. . , July 8, 2024 — MedPharm, Ltd. MedPharm and Tergus Pharma have announced a merger to create a leading CDMO specializing in topical and transepithelial pharmaceuticals, and will continue to operate using the MedPharm name. Find related and similar companies as well as employees by title and much more. View Tergus Pharma (www. , an Ampersand Capital Partners portfolio company, and Tergus Pharma, a Great Point Partners portfolio company, jointly announced today a merger. ft. The combined organization will operate under the MedPharm name, establishing an end-to-end CDMO with robust scientific Companies like Pharmamodeling, S. Tergus is a one-stop solution for your topical formulation development needs. Tergus Pharma is a comprehensive contract service provider for topical pharmaceuticals, specialising in every stage from research and drug development to testing, scale-up, and commercial manufacturing. C. The move will boost the combined firm Tergus Pharma is a comprehensive contract service provider for topical pharmaceuticals, specialising in every stage from research and drug development to testing, scale-up, and commercial manufacturing. It specializes in topical semi-solids and liquids for skin, nasal, otic, ophthalmic, vaginal and rectal routes of drug delivery. and Tergus Pharma, have decided to combine their efforts. -based company that specializes in the development of dermatology, mucosal membrane and other products. MedPharm, a global topical and transdermal CDMO and an Ampersand Capital Partners portfolio company, is merging with Tergus Pharma, a Great Point Partners portfolio company. The merger combines the companies under the MedPharma name, creating a topical and transepithelial CDMO in the process. The merger allows the new company to offer comprehensive drug development and manufacturing services. Use the PitchBook Platform to explore the full profile. Jan 2, 2026 · Explore Tergus Pharma's in-depth company profile, including funding details, key investors, leadership, competitors, and acquisitions. MedPharm and Tergus Pharma merge to form a global CDMO, enhancing end-to-end services in topical and transdermal development and manufacturing. Jul 29, 2024 · Two companies in the drug-development industry, each with operations in Durham, have merged, forming a larger and more integrated contract development and manufacturing organization (CDMO) to serve the topical and transdermal pharmaceuticals sector. Scientists at Tergus come from a variety of backgrounds including topical/transdermal skin delivery, pharmacology, topical formulation development, biology and pharmaceutical sciences. state-of-the-art facility in Durham, NC. L. -based company that specializes in the development of dermatology, mucosal membrane and other products, in a move that boosts the CDMO’s global Tergus Pharma is an end-to-end contract service provider for topical pharmaceutical products supporting early phase research and formulation, drug development, testing, and both clinical and commercial manufacturing at our 100,000 sq. terguspharma. Formulation Development Complete NCE Generic and OTC product development Tergus Pharma opened its new manufacturing facility and headquarters in Raleigh, North Carolina, in May 2021 to expand its commercial manufacturing capabilities in Durham and provide comprehensive solutions, including development and manufacturing services as per the customer changing needs. Similar companies and competitors including the VentureRadar Innovation and Growth scores, Company Information, Location and more. Jul 8, 2024 · MedPharm, a global topical and transdermal CDMO and an Ampersand Capital Partners portfolio company, is merging with Tergus Pharma, a Great Point Partners portfolio company. Tergus Pharma is an end-to-end contract service provider for topical pharmaceutical products supporting early phase research and formulation, drug development, testing, and both clinical and commercial manufacturing at our 100,000 sq. GUILDFORD, United Kingdom and DURHAM, N. Tergus Pharma brings to the partnership expertise in supporting topical pharmaceutical product research, formulation, drug development, testing, and clinical and commercial manufacturing. com) location in North Carolina, United States , revenue, industry and description. Information on acquisition, funding, investors, and executives for Tergus Pharma. Jul 11, 2024 · Tergus Pharma will merge with MedPharm, a U. Together, they are forming a topical and transepithelial contract development and manufacturing . K. npsju, wbuuyx, 1bmq, jo6mz, zv6w, kesi, ndnmt, nexh, mavlad, t1a36x,